2014-04-01 05:19:45 - Steven F. Dowdy, Professor of Cellular and Molecular Medicine at the University of California, San Diego, School of Medicine, to give a presentation titled “Therapeutics: Bioreversible PhosphoTriester siRNN Prodrugs” at the Inaugural Nucleic Acid Research and Development Conference, June 19 & 20, 2014 in San Diego, CA.
Dr. Dowdy received his Ph.D. degree from the University of California, Irvine, where he studied tumor suppression, and did his postdoctoral work with Professor Robert Weinberg at the Whitehead Institute, MIT, on tumor suppressor genes.
Prior to UCSD, Dr. Dowdy was an Assistant Professor at Washington University School of Medicine. His laboratory is focused on understanding the molecular basis of G1 cell cycle deregulation during oncogenesis, and development of novel macromolecular RNAi prodrugs called short interfering RiboNucleic Neutrals (siRNNs) that contain bioreversible phosphotriester protecting groups that are removed by intracellular enzymes to become active RNAi triggers.
This premier conference will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on the latest discoveries
in the Nucleic Acid Field. A balance of both academic and industry experts will facilitate discussion on the following areas:
I. Nucleic Acid as a Drug Target I
II. Emerging Nucelic Acid Technologies
III. Aptamer Design and Application
IV. Nucleic Acid as a Drug Target II
This conference is also part of the 2014 Nucleic Acid Summit which consists of the following co-located conferences:
1. 4th Next-Generation Sequencing Conference
2. Non-Coding RNAs and RNAi Research & Therapeutics
3. Bioinformatics & Pharmacogenomics: Managing and Analyzing Big Data
4. Nucleic Acid Research & Discovery
For more information, please visit www.gtcbio.com/nucleicacid